---
title: "Sangamo Therapeutics (SGMOQ) news: bankruptcy and delisting"
url: "https://aibio.space/companies/sangamo-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "SGMOQ bankruptcy, delisting and offering news: Sangamo ends July in Chapter 11 with $16,906,955 in cash. Sangamo Therapeutics, Inc."
---

SGMOQ Sangamo Therapeutics, Inc. OTC · United States

# Sangamo Therapeutics (SGMOQ) news SGMOQ bankruptcy, delisting and offering news

Distress · 2026-10-27

## [Sangamo ends July in Chapter 11 with $16,906,955 in cash](https://aibio.space/news/sangamo-ends-july-chapter-11-16-906-955-cash/)

An amended monthly operating report for the period ended July 31, 2026 shows $16,906,955 in cash and a July loss of $11,165,298. It also lists an $18 million replacement debtor-in-possession loan.

## Latest Sangamo Therapeutics news

1. 2026-10-15 Listings [Sangamo's Nasdaq delisting becomes final as Chapter 11 case continues](https://aibio.space/news/sangamos-nasdaq-delisting-becomes-final-chapter-11-case-continues/) Nasdaq filed Form 25 on Oct. 7, ending a listing that began unravelling over the minimum bid price. The stock trades OTC as SGMOQ after Sangamo agreed to sell its Fabry program to PTC for $111 million in cash.
2. 2026-10-07 Listings [Nasdaq files SEC notice to remove Sangamo Therapeutics stock from listing](https://aibio.space/news/nasdaq-files-sec-notice-remove-sangamo-therapeutics-stock-listing/) Nasdaq signed the Form 25 itself on October 6, 2026, and the form gives no reason. Sangamo's latest annual report warned it might cease operations, liquidate or seek bankruptcy protection.
3. 2026-08-13 Distress [Sangamo bankruptcy auction brings in $163.55 million from PTC and Lilly](https://aibio.space/news/sangamo-bankruptcy-auction-brings-163-55-million-ptc-lilly/) Winning bids yield about $163.55 million in cash at closing and up to $100 million in milestones. Every sale still needs court approval, and the company is still selling other assets.
4. 2026-06-23 Debt Financing [Sangamo files Chapter 11 with DIP financing from Northridge ATM](https://aibio.space/news/sangamo-files-chapter-11-dip-financing-northridge-atm/) Sangamo filed for Chapter 11 in Delaware on June 23, 2026 and seeks court approval of DIP financing from Northridge ATM, LLC. Eli Lilly and Astellas have signed stalking horse bids for its assets.
5. 2025-05-13 Listings [Sangamo Therapeutics prices $23.0 million offering of stock and warrants at $0.50](https://aibio.space/news/sangamo-therapeutics-prices-23-0-million-offering-stock-warrants-0-50/) Sangamo's underwritten offering is expected to bring in about $23.0 million. The 46,633,393 purchase warrants in the deal outnumber the 12,235,000 common shares, and Cantor Fitzgerald & Co. represents the underwriters.

## Sangamo Therapeutics at a glance

- **Ticker**: SGMOQ

- **Listing**: OTC

- **Country**: United States

- **Cash, Mar 31, 2026**: $27.6 million

### Related companies

- [10x Genomics](https://aibio.space/companies/10x-genomics/) NASDAQ: TXG
- [HeartBeam](https://aibio.space/companies/heartbeam/) NASDAQ: BEATW
- [Modular Medical](https://aibio.space/companies/modular-medical/) NASDAQ: MODD
- [Inspire Medical Systems](https://aibio.space/companies/inspire-medical-systems/) NYSE: INSP
- [AXIM BIOTECHNOLOGIES, INC.](https://aibio.space/companies/axim-biotechnologies/) OTC: AXIM
- [UTAH MEDICAL PRODUCTS INC](https://aibio.space/companies/utah-medical-products/) NASDAQ: UTMD
- [Greenland Mines](https://aibio.space/companies/greenland-mines/) NASDAQ: GRML
- [LAKELAND INDUSTRIES INC](https://aibio.space/companies/lakeland-industries/) NASDAQ: LAKE

### Also on OTC

- [VirExit Technologies](https://aibio.space/companies/virexit-technologies/) VXIT
- [LogicMark](https://aibio.space/companies/logicmark/) LGMK
- [Electromedical Technologies](https://aibio.space/companies/electromedical-technologies/) EMED
- [United Health Products](https://aibio.space/companies/united-health-products/) UEEC
- [Stimcell Energetics](https://aibio.space/companies/stimcell-energetics/) STME
- [BIOFORCE NANOSCIENCES HOLDINGS, INC.](https://aibio.space/companies/bioforce-nanosciences/) BFNH

## Sangamo Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$112.7 million](https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/) | [$111.5 million](https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/) |
| Net income (loss) | [-$122.9 million](https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/) | [-$97.9 million](https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/) |
| Cash from operations | [-$97.2 million](https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/) | [-$67.1 million](https://www.sec.gov/Archives/edgar/data/1001233/000162828026022029/) |
| Cash and equivalents | [$20.9 million](https://www.sec.gov/Archives/edgar/data/1001233/000162828026035067/) | [$41.9 million](https://www.sec.gov/Archives/edgar/data/1001233/000162828026035067/) |

Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $27.6 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Sangamo Therapeutics

Did Sangamo Therapeutics file for bankruptcy?

Our latest story on this, dated Oct 27, 2026: "Sangamo ends July in Chapter 11 with $16,906,955 in cash". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sangamo-ends-july-chapter-11-16-906-955-cash/).

Was Sangamo Therapeutics delisted?

Our latest story on this, dated Oct 15, 2026: "Sangamo's Nasdaq delisting becomes final as Chapter 11 case continues". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sangamos-nasdaq-delisting-becomes-final-chapter-11-case-continues/).

Has Sangamo Therapeutics raised money recently?

Our latest story on this, dated Jun 23, 2026: "Sangamo files Chapter 11 with DIP financing from Northridge ATM". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sangamo-files-chapter-11-dip-financing-northridge-atm/).

What is the ticker symbol of Sangamo Therapeutics?

Sangamo Therapeutics, Inc. trades under the ticker SGMOQ on OTC.

Where is Sangamo Therapeutics listed?

Sangamo Therapeutics, Inc. is listed on OTC.

Which country or territory is Sangamo Therapeutics listed under?

Our directory records Sangamo Therapeutics, Inc. under United States.

Does aibio.space cover Sangamo Therapeutics?

aibio.space lists Sangamo Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Sangamo Therapeutics profitable?

Sangamo Therapeutics, Inc. reported a net loss of $122.9 million for the fiscal year ended Dec 31, 2025, and used $97.2 million of cash in operations, per its annual report to the SEC.

How much does Sangamo Therapeutics spend on research and development?

$112.7 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Sangamo Therapeutics have?

$27.6 million in cash at Mar 31, 2026, per its 10-Q.

What is the latest Sangamo Therapeutics (SGMOQ) stock news?

Our latest story on Sangamo Therapeutics, dated Oct 27, 2026: "Sangamo ends July in Chapter 11 with $16,906,955 in cash". An amended monthly operating report for the period ended July 31, 2026 shows $16,906,955 in cash and a July loss of $11,165,298. It also lists an $18 million replacement debtor-in-possession loan. [Source](https://aibio.space/news/sangamo-ends-july-chapter-11-16-906-955-cash/).

Does Sangamo Therapeutics have debt, a term loan or convertible notes?

Our latest debt story, dated Jun 23, 2026: "Sangamo files Chapter 11 with DIP financing from Northridge ATM". Sangamo filed for Chapter 11 in Delaware on June 23, 2026 and seeks court approval of DIP financing from Northridge ATM, LLC. Eli Lilly and Astellas have signed stalking horse bids for its assets. [Source](https://aibio.space/news/sangamo-files-chapter-11-dip-financing-northridge-atm/).

How long will Sangamo Therapeutics's cash last?

From our story of Oct 15, 2026: The April 29 announcement cited Sangamo's lack of capital resources and its need for substantial additional funding to continue as a going concern. [Source](https://aibio.space/news/sangamos-nasdaq-delisting-becomes-final-chapter-11-case-continues/).

How can I follow Sangamo Therapeutics (SGMOQ) news?

Press Follow on this page to add Sangamo Therapeutics to your Following list, or subscribe to the aibio.space newsletter. We have published 6 stories naming Sangamo Therapeutics so far, in Debt Financing, Distress, Listings.

## Investor discussion: Sangamo Therapeutics

Members talk about Sangamo Therapeutics (SGMOQ). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Sangamo Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-10-27 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000119312526434171/d179328dex991.htm)
2. 2026-10-16 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000119312526423054/d453907dex991.htm)
3. 2026-10-07 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1001233/000135445726000959/xslF25X02/primary_doc.xml)
4. 2026-09-21 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 1.03,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000119312526396644/d178611d8k.htm)
5. 2026-09-08 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 1.03,2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000110465926105905/tm2624942d1_ex99-1.htm)
6. 2026-08-28 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 1.01,1.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000119312526374328/d116527d8k.htm)
7. 2026-08-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1001233/000119312526354282/d168229dnt10q.htm)
8. 2026-08-12 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000119312526346796/d21956dex991.htm)
9. 2026-07-20 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 1.03,3.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000119312526309012/d125683d8k.htm)
10. 2026-07-01 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000119312526292501/d113173d8k.htm)
11. 2026-06-23 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 1.01,1.03,2.03,2.05). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000119312526278582/d161847d8k.htm)
12. 2026-04-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000162828026028128/sgmo-20260428.htm)
13. 2026-02-04 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1001233/000119312526036786/d300116d424b5.htm)
14. 2025-10-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000100123325000015/sgmo-20251029.htm)
15. 2025-05-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018697/ny20048472x3_8k.htm)
16. 2025-05-13 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1001233/000114036125018702/ny20048472x1_424b5.htm)
17. 2025-05-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000162828025022664/sgmo-20250430.htm)
18. 2024-12-30 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000162828024052579/sgmo-20241222.htm)
19. 2024-12-10 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1001233/000162828024050545/sgmo-20241209.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:SGMOQ on TradingView](https://www.tradingview.com/symbols/OTC-SGMOQ/).

## Listing details

Sangamo Therapeutics, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker SGMOQ, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Sangamo Therapeutics, Inc.

- **Ticker**: SGMOQ

- **Listing**: OTC

- **Country or territory**: United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/sangamo-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sangamo Therapeutics (SGMOQ) news: bankruptcy and delisting", 2026-10-31, https://aibio.space/companies/sangamo-therapeutics/